Viekira on blockbuster pace as AbbVie adds 2nd HCV drug
This article was originally published in Scrip
Viekira Pak, AbbVie's fixed-dose combination therapy for hepatitis C, fell short of Wall Street consensus sales estimates during the second quarter, but the Chicago-area pharma company pointed to several factors causing below-expectation US sales, while international sales exceeded projections.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Remdesivir shows ability to yield clinical improvement in moderately ill COVID-19 patients, but data are called ‘modest’ and shorter therapy duration showed better results than longer.
The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.